Long-term outcomes of prostaglandin analog versus timolol maleate in ocular hypertensive or primary open-angle glaucoma patients in Europe

Journal of Ocular Pharmacology and Therapeutics

Volumn 27, Issue 5, 2011, Pages 493-498

  Holló, Gábor ^a   Thelen, Ulrich ^b   Teus, Miguel A ^c   Quaranta, Luciano ^d   Ferkova, Sylvia ^e   Babić, Nikola ^f   Misiuk Hojlo, Marta ^g   Mikropoulos, Dimitrios G ^h   Kaluzny, Bartlomiej J ⁱ   Kozobolis, Vassilios ^j   Januleviciene, Ingrida ^k   Kóthy, Péter ^a   Camara, Cristina ^c   Russo, Andrea ^d   Krzyzanowska Berkowska, Patrycja ^g   Cieślińska, Iwona ⁱ   Stewart, Jeanette A ^l   Kristoffersen, Michael S ^l   Nelson, Lindsay A ^l   Stewart, William C ^l  

^a SEMMELWEIS UNIVERSITY   (Hungary)

^b Private Practice   (Germany)

^c UNIVERSITY OF ALCALÁ   (Spain)

^d UNIVERSITY OF BRESCIA   (Italy)

^e Physics and Informatics   (Slovakia)

^f University Eye Clinic   (Serbia)

^g WROCLAW MEDICAL UNIVERSITY   (Poland)

^h AHEPA UNIVERSITY HOSPITAL   (Greece)

ⁱ NICOLAUS COPERNICUS UNIVERSITY   (Poland)

^j University General Hospital   (Greece)

^k KAUNAS UNIVERSITY OF TECHNOLOGY   (Lithuania)

^l University of South Carolina   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BIMATOPROST; LATANOPROST; TIMOLOL MALEATE; TRAVOPROST;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DRUG COST; EUROPE; FEMALE; HUMAN; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; OPEN ANGLE GLAUCOMA; PRESCRIPTION; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

AGED; AMIDES; ANTIHYPERTENSIVE AGENTS; CLOPROSTENOL; DISEASE PROGRESSION; DRUG COSTS; EUROPE; FEMALE; FOLLOW-UP STUDIES; GLAUCOMA, OPEN-ANGLE; HUMANS; INTRAOCULAR PRESSURE; MALE; MIDDLE AGED; OCULAR HYPERTENSION; PROSTAGLANDINS F, SYNTHETIC; RETROSPECTIVE STUDIES; TIME FACTORS; TIMOLOL; TREATMENT OUTCOME;

EID: 80054858364     PISSN: 10807683     EISSN: 15577732     Source Type: Journal    
DOI: 10.1089/jop.2011.0051     Document Type: Article

References (19)

1. Stewart, W.C., Day, D.G., Stewart, J.A., et al. Therapeutic success of latanoprost 0.005% compared to brimonidine 0.2% in patients with open-angle glaucoma or ocular hypertension. J. Ocul. Phar. Ther. 16:557-564, 2000.
2. Stewart, W.C., Sharpe, E.D., Day, D.G., et al. Comparison of the efficacy and safety of latanoprost 0.005% compared to brimonidine 0.2% or dorzolamide 2% when added to a topical β-adrenergic blocker in patients with primary openangle glaucoma or ocular hypertension. J. Ocul. Phar. Ther. 16:251-259, 2000. (Pubitemid 30366286)
3. Stewart, W.C., Kolker, A.E., Sharpe, E.D., et al. Factors associated with long-term progression or stability in primary open angle glaucoma. Am. J. Ophthalmol. 130:274-279, 2000.
4. Stewart, W.C., Leech, J., Sharpe, E.S., et al. An economic analysis of switching to latanoprost from a b-blocker or adding brimonidine or latanoprost to a b-blocker in openangle glaucoma or ocular hypertension. Am. J. Manag. Care 8:S240-S248, 2002. (Pubitemid 34918724)
5. Stewart, W.C., Hudgins, A.C., Pruitt, C.A., and Sine, C. Daily cost of newer glaucoma agents. J. Ocul. Phar. Ther. 15:379-388, 1999. (Pubitemid 29480955)
6. Tanna, A.P., Rademaker, A.W., Stewart, W.C., and Feldman, R.M. Meta-analysis of the efficacy and safety of alpha2-adrenergic agonists, beta-adrenergic antagonists, and topical carbonic anhydrase inhibitors with prostaglandin analogs. Arch. Ophthalmol. 128:825-833, 2010.
7. Stewart, W.C., and Jenkins, J.N. Predictive value of the efficacy of glaucoma medications in regulatory trials: Phase I-III to post-marketing studies. Eye 22:985-988, 2008.
8. Stewart, W.C., Stewart, J.A., and Mychaskiw, M.A. Costeffectiveness of latanoprost and timolol maleate for the treatment of glaucoma in Scandinavia and the United Kingdom, using a decision-analytic health economic model. Eye 23:132-140, 2009.
9. Book, S.A. Essentials of Statistics. New York, NY: McGraw-Hill, Inc. 1978; p. 205-215.
10. Stewart, W.C., Kolker, A.E., Sharpe, E.D., et al. Long-term progression at individual mean intraocular pressure levels in primary open-angle and exfoliative glaucoma. Eur. J. Ophthalmol. 18:765-770, 2008.
11. Bengtsson, B., Leske, M.C., Hyman, L., and Heijl, A. Early Manifest Glaucoma Trial Group. Fluctuation of intraocular pressure and glaucoma progression in the early manifest glaucoma trial. Ophthalmology 114:205-209, 2007. (Pubitemid 46161799)
12. Levine, R.A., Demirel, S., Fan, J., et al. Ocular Hypertension Treatment Study Group. Asymmetries and visual field summaries as predictors of glaucoma in the ocular hypertension treatment study. Invest. Ophthalmol. Vis. Sci. 47:3896-3903, 2006. (Pubitemid 46044305)
13. Camras, C.B. Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma: A six-month, masked, multicenter trial in the United States. Ophthalmology 103:138-147, 1996. (Pubitemid 26046170)
14. Netland, P.A., Landry, T., Sullivan, E.K., et al. Travoprost compared with latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension. Am. J. Ophthalmol. 132:472-484, 2001. (Pubitemid 32904567)
15. McLeod, C., Bagust, A., Boland, A., et al. Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: A systematic review and economic evaluation. Health Technol. Assess. 11:1-158, 2007.
16. Strmen, P., Jancus, V., Okkelová , J., and Tvrdonová, M. Clinical trial of the generic product UNILAT following its efficiency and safety in glaucoma and intraocular hypertension. Cesk. Slov. Oftalmol. 66:258-261, 2010.
17. Watson, P., and Stjernschantz, J. A six-month, randomized, double-masked study comparing latanoprost with timolol in open-angle glaucoma and ocular hypertension. The Latanoprost Study Group. Ophthalmology 103:126-137, 1996. (Pubitemid 26046169)
18. Alm, A., and Stjernschantz. J. Effects on intraocular pressure and side effects of 0.005% latanoprost applied once daily, evening or morning. A comparison with timolol. Scandinavian Latanoprost Study Group. Ophthalmology 102:1743-1752, 1995. (Pubitemid 26004426)
19. Costagliola C, Parmeggiani F, and Sebastiani A. Assessing the cost-effectiveness of switching from a beta-blocker to latanoprost in the treatment of ocular hypertension. Expert. Opin. Pharmacother. 4:1775-1788, 2003. (Pubitemid 37322362)